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Antiretrovirals that reach higher concentrations in cerebrospinal fluid (CSF) are associated with better control of HIV in CSF
and possibly better neurocognitive performance. The objective of this study was to determine whether amprenavir (APV) con-
centrations in CSF are in the therapeutic range. Individuals were selected based on the use of regimens that included fosampre-
navir (FPV), a prodrug of APV, and the availability of stored CSF andmatched plasma. Total APV was measured in 119 matched
CSF-plasma pairs from 75 subjects by high-performance liquid chromatography (HPLC) (plasma) or liquid chromatography
tandemmass spectrometry (LC/MS/MS) (CSF). Concentrations were compared to the 50% inhibitory concentration (IC50) for
wild-type HIV (5.6 ng/ml). Subjects were predominantly middle-aged (median 44 years) white (57%)men (78%) with AIDS
(77%). APV was detected in all but 4 CSF specimens, with a median concentration of 24.8 ng/ml (interquartile range [IQR], 16.2
to 44.0). The median CSF-to-plasma ratio was 0.012 (IQR, 0.008 to 0.018). CSF concentrations correlated with plasma concentra-
tions (rho 0.61; P< 0.0001) and with postdose sampling interval (rho0.29; P 0.0019). APV concentrations in CSF ex-
ceeded the median IC50 for wild-type HIV inmore than 97% of CSF specimens with detectable APV by a median of 4.4-fold (IQR,
2.9 to 7.9). We conclude that administration of fosamprenavir should contribute to control of HIV replication in the central ner-
vous system (CNS) as a component of effective antiretroviral regimens.
The central nervous system (CNS) is infected early in the courseof HIV disease, andHIV RNA is often detected in the cerebro-
spinal fluid (CSF) of untreated individuals with chronic disease.
CNS infection can lead to HIV-associated neurocognitive disor-
ders (HAND), which remain common despite potent combina-
tion antiretroviral therapy (ART) (8). HIV and the resulting im-
mune and glial responses are likely to be important factors in the
pathogenesis of HAND, leading to structural and functional syn-
aptodendritic changes (15). Supporting the importance of the vi-
rus in the pathogenesis of HAND, HIV RNA concentrations in
CSF are higher in patients with cognitive impairment than in
those without impairment in cross-sectional and longitudinal
studies (6, 7, 16), although the association has weakened in the
highly active ART (HAART) era (20).
Antiretroviral drugs differ in their distribution—or penetra-
tion—into the CNS, with some drugs penetrating at concentra-
tions similar to those in plasma and others penetrating at less than
1% of those in plasma. Only antiretrovirals that reach therapeutic
concentrations in the CNS should be able to reduce HIV replica-
tion in that compartment. Factors such as molecular weight, lipo-
solubility, protein binding, and transmembrane transport all af-
fect CNS penetration of antiretrovirals. Antiretrovirals that reach
higher levels in CSF are associated with better control of HIV
replication (10, 14) and often with better neurocognitive perfor-
mance (4, 12, 13, 21), although not all reports agree (14).
HIV protease inhibitors are highly bound to plasma proteins
and are substrates for P-glycoprotein (9). Perhaps as a result, pro-
tease inhibitors have the lowest fractional penetrance (i.e., the
amount of drug reaching the CSF compartment) into CSF of the
antiretroviral drug classes. The limited distribution of protease
inhibitors into the CNS may be mitigated by the substantial po-
tency of these drugs. One protease inhibitor, fosamprenavir
(FPV), a phosphorylated prodrug of amprenavir (APV), has low
plasma protein binding (90%) relative to other drugs in its class.
The objectives of this study were to measure APV concentrations
in CSF, to compare them with matched plasma concentrations,
and to estimate the efficacy of APV in the CNS by comparing the
drug’s concentrations in CSF to the in vitro 50% inhibitory con-
centration (IC50) range for wild-type HIV-1.
MATERIALS AND METHODS
CSF-plasma specimen pairs were selected from subjects who had HIV-1
infection and who had enrolled in parent observational cohort studies
conducted at or coordinated by the University of California, San Diego,
between July 2004 and January 2009. An optional lumbar puncture was
part of the design of those parent studies. These cohort studies included
the CNS HIV AntiRetroviral Therapy Effects Research (CHARTER) and
the California NeuroAIDS Tissue Network (CNTN) projects. Selection
criteria included use of FPV and availability of stored CSF and matched
plasma obtained within 16 h (for FPV twice-daily [BID] dosing) and 24 h
(for FPV once-daily dosing) of self-reported dosing. Oral FPV was dosed
at 700 mg twice daily with ritonavir (RTV) 100 mg twice daily (n 62),
1,400 mg once daily with ritonavir 200 mg once daily (n 34), or 1,400
mg twice daily without RTV (n 23). The UCSD Human Research Pro-
tections Program approved this research. Informed consent was obtained
from all subjects.
CSF was obtained by lumbar puncture performed with an aseptic
technique using a 22-gauge pencil-point needle by experienced operators.
Blood was obtained within 1 h of CSF by routine phlebotomy. All speci-
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mens were stored at 70°C until analysis. Total APV was measured by
high-performance liquid chromatography (HPLC) (in plasma) and liquid
chromatography tandem mass spectrometry (LC/MS/MS) (in CSF). The
dynamic ranges of these assays were 3.9 to 2,000 ng/ml (plasma) and 0.39
to 200 ng/ml (CSF). APV concentrations in CSF were compared to the in
vitro IC50 range for wild-type HIV, including the median (5.6 ng/ml) and
the 99th percentile (16.7 ng/ml) of the IC50 range (17). HIV RNA was
quantified by reverse transcription-PCRusing aRocheTaqManRealTime
assay (Roche Diagnostics) with a lower limit of detection of 50 copies/ml
(1.7 log10 copies/ml). Peripheral bloodCD4
T cells were counted by flow
cytometry. Adequate adherence was defined as subjects taking 95% of
their scheduled antiretroviral drugs over 4 days preceding the CSF and
blood specimen collection and was based on self-reporting. Data were
analyzed with descriptive, bivariable, and multivariable statistics using
standard methods (JMP; SAS Institute, Cary, NC). Spearman’s correla-
tion coefficient was used to assess the relationship between plasma and
CSF APV concentrations. Descriptive statistics were calculated using all
data available. To eliminate bias due to interindividual differences in the
numbers of CSF-plasma pairs, certain statistical analyses, such as the anal-
ysis comparing dosing schedule to APV concentrations, were limited to
one time point per subject. By convention, we selected the earliest time
point for each subject for these analyses.
RESULTS
A total of 119 CSF-plasma pairs were obtained from 75 subjects.
Most subjects provided either one (n 52) or two (n 14) spec-
imen pairs. The remaining 9 subjects provided 3 (n 5), 4 (n
1), 5 (n  1), 6 (n  1), and 9 (n  1) pairs. Subjects were pre-
dominantly middle-aged (median age of 44 years; interquartile
range [IQR], 39 to 51) white (57%)men (78%) with AIDS (77%).
The median CD4 cell count at the time of sampling was 413/
mm3 (IQR, 279 to 542), with 11% of values falling below 200/
mm3. The median nadir CD4 cell count was 105/mm3 (IQR, 15
to 227). Disease severity based on the 1993 Centers for Disease
Control and Prevention classification systemwas categorized as C
for 56%, B for 30%, and A for 14%. HIV RNAwas at or below the
detection limit (1.70 log10 copies/ml) in 57% of plasma and 88%
of CSF specimens.
The median duration of FPV use was 9.5 months (IQR, 3.1 to
20.1). Concurrent antiretrovirals included nucleoside or nucleo-
tide reverse transcriptase inhibitors (NRTIs) in all subjects, a non-
NRTI in 13%, an additional protease inhibitor other than ritona-
vir in 11%, and one fusion inhibitor in 1%. The self-reported FPV
dose before sampling was taken with food at 83% of the sampling
time points. Adherence informationwas available for 85 sampling
time points, and adequate adherence was reported for 75 (87%).
APV concentrations in plasma and CSF are displayed in Fig. 1,
and aggregate data are summarized in Table 1, including both
overall results and results by FPV dosing schedule. APV was not
detected in four CSF specimens, while the corresponding plasma
had detectable APV. The median CSF APV concentrations with
and without RTV (including both FPV dosing schedules) were
26.1 ng/ml (IQR, 16.9 to 45.8) (not shown in table) and 23.4 ng/ml
(IQR, 10.7 to 41.5), respectively. The data for the timing of CSF
sampling were evenly distributed over the dosing intervals, and
the median postdose sampling intervals ( standard deviation
[SD]) were 7.2 5.2 h for CSF and 6.9 5.2 h for plasma. APV
was detectable in all but four CSF specimens. CSF fractional pen-
etrance (i.e., the amount of drug reaching the CSF compartment)
was 1.2% of the median total plasma APV concentration (IQR,
0.8% to 1.8%). APV concentrations in CSF correlated with those
in plasma (rho 0.61; P 0.0001) (Fig. 2) with persistent statis-
tical significance in subgroups with (rho 0.63; P 0.0001) and
without (rho  0.57; P  0.005) RTV. Further, correlations re-
mained consistently strong when correlative analyses were per-
formed using postdose sampling interval quartiles ranging from
0.5 to 5, 5 to 7, 7 to 12, and 12 to 23 h. The correlation weakened
slightly for the shortest postdose sampling interval range of 0.5 to
5 h, but the coefficient (rho 0.30)was greater than 0.25 although
not statistically significant (P  0.123). APV concentrations in
plasma and CSF correlated with the postdose sampling interval
(rho0.25 [P 0.0054] and0.29 [P 0.0019], respectively).
The CSF-to-plasma ratio did not change significantly across the
dosing interval (rho0.12; P 0.22). RTV-boosted FPV reg-
imens were associated with higher plasma concentrations of APV
compared to FPVwithout RTV (t 1.61; P 0.058) but not with
higher CSF concentrations (t 1.07;P 0.15). These results were
not substantially different when the analyses were performed with
inclusion of a single time point for subjects with multiple CSF-
plasma pairs.
APV concentrations inCSF exceeded themedian IC50 for wild-
type HIV-1 in 97.3% of specimens with detectable APV by a me-
dian of 4.4-fold (IQR, 2.9 to 7.9), while 73.9% of the same speci-
mens had concentrations above the 99th percentile of the IC50
range. Higher APV concentrations in plasma were not associated
with undetectable HIV RNA levels in plasma (t 0.42; P 0.34).
Overall, higher APV concentrations in CSF were not associated
with undetectableHIVRNA inCSF (t 1.5;P 0.15).Of note, all
HIV RNA levels in CSF were undetectable when HIV RNA levels
in plasma were undetectable. In the subgroup of subjects who had
detectable HIV RNA levels in plasma, detectable HIV RNA levels
in CSF trended toward an association with lower APV concentra-
tions in CSF (mean, 24.5 versus 37.5 ng/ml [t1.8; P 0.08]).
This association was present ( 0.04; P 0.08) inmultivariable
analyses that accounted for APV concentrations in plasma, dura-
tion of FPV therapy, and postdose sampling time. Classification
and regression trees showed that all of the detectable HIV RNA
FIG 1 Amprenavir concentrations by fosamprenavir dosing schedule in
plasma (dark shading) and CSF (light shading) by postdose sampling time.
The horizontal solid line represents the median IC50 (5.6 ng/ml) and the hor-
izontal dashed line the IC50 99th percentile (16.7 ng/ml). Plasma concentra-
tions below 300 ng/ml and corresponding CSF data were excluded from the
graph.
Croteau et al.
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levels in CSF occurred in subjects who had APV concentrations in
CSF below 53.5 ng/ml. This equated to a CSF-to-IC50 ratio of 9.6.
In other words, all detectable HIV RNA levels in CSF occurred in
subjects whose APV concentrations in CSF exceeded the 50% in-
hibitory concentration by less than 9.6-fold. This categorical ex-
pression of CSF APV concentrations was statistically significantly
associated with detectable HIV RNA levels in CSF (  12.5;
P 0.01) in multivariable analyses that accounted for APV con-
centrations in plasma, duration of FPV therapy, and postdose
sampling time.
FPV dosing schedules were associated with different CSF and
plasmaAPV concentrations as well as CSF-to-plasma andCSF-to-
IC50 ratios as shown in Table 1 and Fig. 3. While FPV at 700 mg
BID with RTV resulted in the highest median CSF APV concen-
tration, the other FPV dosing schedules did not substantially dif-
fer. However, FPV at 1,400 mg BID without RTV had the highest
CSF-to-plasma ratio, with trends toward significance (Fig. 3). FPV
at 1,400 mg BID without RTV appeared to be associated with
lower plasma APV concentrations, although the differences com-
pared to other dosing schedules were not statistically significant.
DISCUSSION
APVCSF concentrations have not been reported previously other
than in a much smaller series with a median CSF APV concentra-
tion comparable to the one reported here (19). In this study, APV
concentrations in plasma were somewhat variable whereas APV
concentrations in CSF were more stable and exceeded the median
concentration required to inhibit wild-type HIV in vitro in nearly
all specimens regardless of dosing schedules (median, 4.4-fold
TABLE 1 Summary of amprenavir concentrations and sampling by fosamprenavir dosing schedule
Parameter




or IQRCSF Plasma (overall)
Regimen
FPV 700 mg BID, with RTV 60 62 60 60
FPV 1,400 mg once a day, with RTV 33 34 33 33
FPV 1,400 mg BID, no RTV 22 23 22 22
Total 115 119 115 115
Median
FPV 700 mg BID, with RTV 31.6 2,230 0.014 4.2
FPV 1,400 mg once a day, with RTV 20.5 2,460 0.010 3.7
FPV 1,400 mg BID, no RTV 23.4 1282 0.018 5.6
Overall 24.8 2,261 0.012 4.4
IQR
FPV 700 mg BID, with RTV 18.3–51 1,459–3,559 0.009–0.018 1.9–7.4
FPV 1,400 mg once a day, with RTV 14.9–35.2 1,556–3,185 0.007–0.012 2.7–6.3
FPV 1,400 mg BID, no RTV 10.7–41.5 718–3,108 0.008–0.031 3.3–9.1
Overall 16.2–44.0 1,397–3,353 0.008–0.018 2.9–7.9
FIG 2 Correlation between amprenavir CSF and plasma concentrations.
FIG 3 CSF-to-plasma ratios of amprenavir concentrations by fosamprenavir
dosing schedule, including only the first time point for subjects with multiple
time points. QD, once daily.
Therapeutic Amprenavir Concentrations in CSF
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higher). In addition, the majority of specimens exceeded the 99th
percentile of the IC50 range. The concentrations of APV in CSF
were lower than expected based on the drug’s physicochemical
characteristics. For example, APV has a relatively low binding
(90%) to plasma proteins such as albumin and alpha-1 acid gly-
coprotein compared to other drugs in its class (18). Therefore,
assuming all unbound drug penetrates into the CSF, one would
expect the CSF concentrations to be approximately 10% of those
in plasma. The lower-than-expected CSF fractional penetrance of
1.2% indicates that limiting factors restrict distribution of APV
into the CSF, which is similar to what has been seen previously
with other protease inhibitors (2, 3, 11). APV affinity for active
efflux transporters such as P-glycoprotein may be one of those
barriers (1, 22). Despite this limitation, the CSF fractional pen-
etrance still compares well to that of other protease inhibitors.
The moderate-to-strong correlation between APV concentra-
tions in CSF and plasma suggests that APV concentrations in
plasma would be useful for estimating concentrations in the CNS
and suggests that interventions focused on increasing APV con-
centrations in plasmamight also result in higher concentrations in
the CNS. Theweakening of the correlation coefficient (although it
was still greater than 0.25) observed for the shortest postdose sam-
pling interval quarter may indicate the presence of some system
hysteresis for the CSF compartment, particularly at the beginning
of the dosing interval, perhaps suggesting achievement of mini-
mum concentrations in CSF while plasma concentrations are ris-
ing. The finding of a low proportion of CSF specimens with de-
tectable HIV RNA further supports the idea of the effectiveness of
APV in the CNS. However, the latter should not necessarily be
attributed to APV, since other factors, particularly the presence of
other antiretroviral agents in each drug regimen, may have ac-
counted for the finding. Disease-related variables may have also
accounted for the finding. For example, participants had relatively
good immune reconstitution (89% had CD4 T-cell counts 
200/mm3), which has been linked toHIV inCSF beingmore likely
to originate from migrating lymphocytes (i.e., a predominant
blood source) than frommacrophages and microglia in brain tis-
sue (i.e., a predominant CNS source) (5, 23).
Analyses of FPV dosing schedules indicated that coadministra-
tion of RTV may increase APV concentrations in plasma to a
greater extent than it increases APV concentrations in CSF, result-
ing in lower CSF-to-plasma APV ratios. Multiple explanations for
this finding are possible. Active efflux transporters at the level of
the blood-brain and blood-CSF barriers may not be saturated un-
der conditions of lower APV concentrations in plasma, with the
result that higher concentrations are more efficiently pumped out
of the CNS. A non-mutually exclusive explanation is that active
efflux transportersmay become upregulated in response to higher
concentrations of substrate or as result of RTV induction. One
possible conclusion from this finding is that higher doses of un-
boosted FPV may result in higher APV concentrations in CSF,
which may better ensure suppression of HIV replication in the
CNS. Four specimens had APV below the lower limit of quantita-
tion in CSF, and all had a relatively short postdose sampling inter-
val (postdose sampling intervals of 2.0, 2.1, 6.2, and 7.8 h), possi-
bly suggesting that those may represent the minimum CSF
concentration ([Cmin] as opposed to the trough concentration.
This may be the result of system hysteresis pertaining to the CSF
compartment), whichmay explain the discrepancywith respect to
plasma concentrations. Subjects with these low levels of APV in
CSF early in the postdose interval were no more likely to use one
dosing schedule of FPV than another.
Compared to other protease inhibitors, FPV appears to have
intermediate distribution into the CNS based on fractional pen-
etrance (higher than atazanavir penetrance and lower than indi-
navir or darunavir penetrance). APV’s CSF-to-IC50 ratio is nu-
merically lower than that of lopinavir, darunavir, or indinavir and
higher than that of atazanavir, but the clinical value of this mea-
sure is unproven (2, 3, 11). Even though APV has the lowest mo-
lecular weight of the HIV protease inhibitors currently in use and
a relatively high unbound fraction—characteristics that should
favor excellent CSF distribution—these characteristics may be
mitigated by APV’s average liposolubility relative to those of other
protease inhibitors and the P-glycoprotein active efflux transport-
er’s affinity for APV. Despite these findings, more than 97% of
CSF specimens hadAPV concentrations that exceeded themedian
IC50 for wild-type HIV, almost 75% of concentrations were above
the 99th percentile of the IC50 range, and nearly 90% of CSF spec-
imens had undetectable HIV RNA (often when HIV RNA was
detectable in plasma), supporting the idea of APV’s antiviral ef-
fectiveness in the CNS, although other antiretrovirals may have
been contributing to those findings.
In summary, our findings provide supporting evidence that
APV reaches therapeutic concentrations in the CNS and, there-
fore, that FPV should be an effective component of antiretroviral
regimens that aim to control HIV replication in this pharmaco-
logically restricted compartment. The data presented in this re-
port support an intermediate position for fosamprenavir relative
to other protease inhibitors in terms of CNS penetration effective-
ness, but this conclusion requires validation with a clinical trial
that would directly compare FPV to another protease inhibitor(s).
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